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Drosophila melanogaster provides an important resource for in vivo modifier screens of neurodegenerative diseases.
To study the underlying pathogenesis of Alzheimer’s disease, fly models that address Tau or amyloid toxicity have
been developed. Overexpression of human wild-type or mutant Tau causes age-dependent neurodegeneration,
axonal transport defects and early death. Large-scale screens utilizing a neurodegenerative phenotype induced by
eye-specific overexpression of human Tau have identified several kinases and phosphatases, apoptotic regulators
and cytoskeleton proteins as determinants of Tau toxicity in vivo. The APP ortholog of Drosophila (dAPPl) shares the
characteristic domains with vertebrate APP family members, but does not contain the human Aβ42 domain. To
circumvent this drawback, researches have developed strategies by either direct secretion of human Aβ42 or triple
transgenic flies expressing human APP, β-secretase and Drosophila γ-secretase presenilin (dPsn). Here, we provide a
brief overview of how fly models of AD have contributed to our knowledge of the pathomechanisms of disease.
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Alzheimer’s disease (AD) is the most common irreversible
cause of dementia. It is characterized by cognitive impair-
ment and progressive neurodegeneration and affects more
than 24 million people worldwide [1]. With AD diagnoses
being on the rise, burdening existing healthcare support
mechanisms, the disease is set to wreak havoc on the
healthcare industry. Definite diagnosis of AD requires
the correct identification of classical neuropathological
hallmarks, which are extracellular amyloid plaques and
intracellular neurofibrillary tangles.
Plaques are primarily composed of Amyloid-β peptides
(Aβ) generated by differential proteolytic cleavage of the
transmembrane receptor Amyloid Precursor Protein (APP).
The endoproteolysis is performed by the β-site APP-
cleaving enzyme (BACE) and γ-secretases, consisting
of Presenilin 1/2, Nicastrin, APH-1 and PEN-2 [2]. Among
other peptides and proteins, the two cleavage products
Aβ40 and Aβ42 are found in plaques. However, Aβ42 is
the predominant form and is considered to be the main
amyloidogenic peptide as it forms fibrils more easily [3].* Correspondence: avoigt@ukaachen.de
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reproduction in any medium, provided the orThe neurofibrillary tangles are composed of hyperpho-
sphorylated Tau proteins and are found intracellularly in
affected neurons. In non-disease situation, Tau is bound to
microtubuli (MT) and thereby leads to the stabilization of
MT. The affinity of Tau to MT is regulated by phosphoryl-
ation of Tau’s MT binding sites. A high degree of phosphor-
ylation results in detachment from MTand subsequent Tau
aggregation, finally causing the formation of neurofibrillary
tangles [4].
The dominating, but not exclusive explanation for the
molecular basis of AD pathology is the amyloid cascade
hypothesis. It states that the deposition of Aβ in the brain
is the central event initiating disease progression [5]. Aβ
deposits activate downstream neurotoxic mechanisms
including deregulation of Tau-MT-binding properties.
The amyloid cascade hypothesis is supported by the fact
that mutations implicated in familial AD are known to
increase ratios of Aβ42/Aβ40 and aggregation [6-8].
Although Tau mutations lead to neurodegeneration [9],
none of the disease-linked Tau mutations is linked to
familial AD. Mutations in Tau rather cause fronto-temporal
dementia or progressive nuclear palsy in which Aβ42
deposits are absent [10].
Several lines of evidence support the idea that Tau acts
downstream of Aβ42 toxicity. Clearance of Aβ reducedl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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transgenic mice, whereas increasing Tau burden did not
affect Aβ42 accumulation [11]. Furthermore, it is known
that reduction of Tau protein levels leads to an amelioration
of Aβ-induced learning and memory impairment [12].
Mechanisms linking extracellular Aβ42 to intracellular
Tau are a subject of intensive research. One possible molecu-
lar mechanism is associated with a dendritic function of
Tau [13]. Dendritic Tau targets Fyn kinase to postsynaptic
density, where Fyn facilitates stabilization of a complex
triggering downstream excitotoxic signaling [13].
In modern research several model systems have been
developed trying to reveal molecular mechanisms linking
pathological hallmarks like aggregating Tau and Aβ pep-
tides to neurodegeneration finally resulting in progressive
memory loss as observed in AD. However, key features of
the disease etiology still remain elusive and no efficient
therapy has been found so far.
This review summarizes the utilization of Drosophila
melanogaster to mimic AD pathology inflicted by excess
Tau protein and Aβ42 peptide production.
Drosophila as a model organism for AD
Animal model systems are used to study specific functional
aspects of human diseases in general and neurodegenera-
tive diseases in particular. AD models range from yeast
[14] and Caenorhabditis elegans [15] to mammals and
human cell culture systems [16-18]. However, no model
system combines easy use and essential criteria of AD,
like cognitive and behavioral dysfunction caused by cell
type-specific neurodegeneration, cellular pathophysiology
including aggregate formation, clear pattern of inheritance
and genetic homogeneity. Although vertebrate model
organisms reflect pathologic hallmarks of human diseases
very well, these model organisms have the disadvantage
of care, time and cost-intensive handling. Using comparable
short-lived model organisms allows fast data acquisition
facilitating large-scale experiments, although these organ-
isms might lack some pathophysiological characteristics
of AD (a summary of invertebrate AD models is pro-
vided in [19]).
Drosophila has more than a hundred-year history in
genetic research [20]. It is used as prime model organism
for experimental studies of multi-cellular eukaryotic biology
and it combines genetic, anatomic, behavioral, methodical
and even economic advantages. It is one of the first organ-
isms with a fully sequenced genome [21]. Approximately
13,600 protein-coding genes are located in only four
chromosomes. The fly anatomy is well studied, its brain
and nervous system are quite complex [22]. Its anatomical
features like the compound eye allow easy access for
phenotypic characterization. The fly’s behavior ranges from
simple avoidance to learning and memory [23]. Due to its
long history as an animal model in research, a wide varietyof well-established molecular genetics tools are available
[24]. Another advantage regarding its usefulness in
biomedical research, especially in the field of neurode-
generative diseases, is its short lifespan. Depending on
diet and stress it ranges up to an average maximum of
120 days. All this makes Drosophila an ideal organism to
study neurodegenerative diseases like AD [25]. Previous
studies have clearly shown that the expression of disease-
related gene products (Tau protein and Aβ42 peptide,
respectively) causes phenotypes in flies. Reminiscent of the
situation observed in AD patients, flies show a robust de-
cline of neurons upon Aβ42 and/or Tau overexpression.
Depending on the neuronal subset the expression of the
AD-linked peptides/proteins is targeted to, the neuronal
decline has different phenotypic outcomes like early death,
reduced locomotion in larvae and adults, decreased flight
ability, blindness, rough eye texture, etc. All these parame-
ters can be analyzed and quantified, thus making the fly
a reasonable organism to study specific aspects of AD
pathology. In addition, more sophisticated behavioral or
cognitive assays can be performed in flies. Applying such
assays on fly models of AD, a decline in cognition, a
hallmark of AD was observed. Overall, the fly is a
powerful model to study the molecular basis of neuronal
decline in the context of AD [26,27]. Tests on alterations
in behavior and/or cognition are possible in flies. However,
their analysis is often time-consuming and the conclusions
that can be drawn with regard to humans are fairly limited.
An overview of advantages and disadvantages using Dros-
ophila as a model organism to study neurodegenerative
diseases like AD is provided in Table 1.
Drosophila models for Aβ toxicity
Comparative analysis of whole genomes revealed striking
similarities between structural composition of human and
Drosophila genes [28]. Nearly 70% of human disease-
causing genes have orthologs in the fly [29]. Given this,
it is not surprising that orthologs associated to known
AD genes not only exist in Drosophila, but also exhibit
functional conservation.
Drosophila harbors an APP ortholog [30] and all
components of the γ-secretase complex [31]. Although
a β-secretase-like enzyme was identified in flies [32], it
displays very low β-secretase activity [33]. The Drosophila
APP ortholog dAPPl shares the characteristic domains with
vertebrate APP family members [30]. However, the region
corresponding to the Aβ peptides lacks significant hom-
ology [30]. As a consequence, there is no endogenous
Aβ production in the fly. Nevertheless, overexpression
of the β-secretase-like protein resulted in cleavage of dAPPl
producing a fragment corresponding to the human Aβ
peptide [32]. Interestingly, this fragment is also able to
aggregate and induces age-dependent behavioral deficits
and neurodegeneration [32].
Table 1 Advantages and disadvantages of using Drosophila as a model organism for neurodegenerative diseases
like AD
Advantage Disadvantage
No ethical
problems/no restrictions according to animal protection laws
Brain anatomy, cardiovascular system and
respiration systems differs substantially from humans
Easy and cheap to maintain
in large quantities, time and cost effective handling
No easy measure of complex behavior
Genetic manipulation is fast
and inexpensive (3 month, < $ 500 per transgene)
Only basic measures of cognitive decline
Plethora of available
resources/stocks (e.g. genome-wide RNAi-library)
Sometimes poor
conservation of proteins/protein function
Short generation time (~10 days),
short life span (2–3 month)- > easy to use for screens
Maintenance as living cultures only,
no permanent conservation (e.g. frozen stocks) possible
Fully sequenced and annotated genome Less complex and adaptive
immune system as in vertebrates
Good conservation of basic
signaling pathways and cellular processes in general
Effects of drugs on the organism might differ
strongly (e.g. conversion of pro-toxins to toxins in liver)
Low redundancy/reduced
number of paralogous genes compared to vertebrates
Probably best
analyzed/understood multi- cellular organism
More complex
organism compare to C. elegans and yeast
Balancer chromosomes allow
the maintenance of mutations/trangenes without genotyping
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flies have been generated to study human Aβ42-induced
toxicity and neurodegeneration [34-37]. Greeve and co-
workers generated a triple transgenic fly expressing human
APP (hAPP), human β-secretase (hBACE) and Drosophila
γ-secretase presenilin (dPsn) with point mutations corre-
sponding to familial AD mutations N141I, L235P and
E280A [36,38]. These flies developed age-dependent
neurodegenerative phenotypes such as photoreceptor
cell loss, severe degeneration of their projecting axons
and early lethality. Co-expression of hAPP and hBACE
favored the processing of a higher glycosylated species of
hAPP in Drosophila resulting in Aβ40 and Aβ42 peptide
forming plaques in transgene expressing tissue. Plaque
deposition precedes the onset of neurodegeneration and
coexpression of mutant dPsn results in acceleration of
photoreceptor degeneration [36]. The described triple
transgenic model clearly demonstrates the similarities
between the biochemical pathways induced by Aβ42
deposition in flies and humans.
A more direct approach to investigate Aβ42-induced
toxicity was used by Crowther and co-workers [34]. They
fused Aβ40/42 peptides to the signal peptide of endogen-
ous Drosophila necrotic gene sequence ensuring secretion
[34]. Using the UAS/Gal4 inducible gene expression system
(Figure 1), the authors generated transgenic flies allowing
the spatiotemporal expression of Aβ40 and Aβ42. As the
expressed Aβ40/42 correspond to the peptides generatedby amyloidogenic processing of APP, influences that might
result from APP processing are avoided. These flies have
the major advantage of a direct assessment of Aβ toxicity.
Neuronal expression of Aβ42 caused neurotoxicity,
locomotion defects and reduced lifespan. Moreover,
intra- and extracellular accumulation of Aβ42 peptides
was observed. Overexpression of Aβ42[E22G], known to
increase the rate of Aβ42 aggregation [7], exacerbated the
observed phenotypes [34]. Extensive investigation of
molecular mechanisms leading to changes in synaptic
transmission and protein composition at the presynaptic
active zone revealed that Aβ42 expression affected axonal
transport of mitochondria and resulted in depletion of
mitochondria from the presynaptic active zone [48]. Intra-
neural accumulation of Aβ42 was shown to reduce synaptic
vesicle release probability prior to bouton loss [49]. Patch
clamp analysis revealed a depression of cholinergic synapses
upon Aβ42 expression. Moreover, expression of a familial
AD-linked mutant variant Aβ[E22G] caused an increased
aggregation of the Aβ42 peptide [50].
Finelli and co-workers established fly lines expressing
fully processed, secreted Aβ peptides [35]. The generated
transgenes allowed in-depth analysis of Aβ accumulation
as overexpression of human Aβ40 and Aβ42 peptides can
be induced in a variety of cell types including neuronal
cells. Both peptides accumulated in the fly brain but only
Aβ42 formed deposits [51]. Consequently, only Aβ42
expressing flies show age-dependent and dose-dependent
Figure 1 Genetic tools in Drosophila. In Drosophila the UAS/Gal4 expression system has been used extensively to express endogenous and
exogenous sequences in the tissue of interest [39]. This is implemented using two different lines. The so-called driver line contains a Gal4 coding
sequence inserted downstream of a promoter of an endogenous Drosophila gene. Gal4 is a transcription factor originating from Saccharomyces
cerevisiae [40]. It specifically binds to promoter elements termed upstream activating sequence (UAS), thus activating expression of the downstream
target sequence [40,41]. A collection of Gal4 driver lines which display a great variety of Gal4 expression in numerous tissues and organs is available to
the public [42]. Frequently used are the glass multimer reporter (GMR) driver inducing retinal expression [43] and the elav driver inducing pan-neuronal
expression [44]. After crossbreeding both, the Gal4 driver and the UAS line, the UAS target sequences will be expressed in a spatiotemporal manner
(depending on the Gal4 driver used). EP-elements are randomly inserted in the fly genome and contain UAS sites. Depending on the orientation
EP-elements might facilitate activation (same orientation) or inactivation (reverse orientation) of neighboring genes in a Gal4-dependent manner. There
are various collections of EP strains available allowing misexpression of a large number of fly genes [45,46]. So-called RNAi lines express short inverted
repeat sequences under UAS control. The sequence of the inverted repeat corresponds to an endogenous gene. Gal4-dependent expression of the
inverted repeat results in the formation short hairpin RNAs (shRNAs). The presence of shRNAs initiates a series of cellular mechanisms eventually
resulting in silencing of the corresponding endogenous gene by RNA interference (RNAi) [47].
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impaired, obvious locomotor deficits appeared in aged
flies and survival was reduced [37].
As memory loss is a well-known feature of AD in
humans, memory assessment is widely used as an adequate
tool to identify factors involved in Aβ42 pathomechanisms.
Recently, excess epidermal growth factor receptor (EGFR)
was shown to enhance short-term memory loss in flies
concomitantly expressing Aβ42. The detrimental effect of
EGFR overexpression on Aβ42-induced memory loss was
verified by the application of known EGFR inhibitors, e.g.
gefitinib and erlotinib. Both drugs are normally used in
clinical cancer therapy, but were able to prevent Aβ42-
induced memory loss in flies. Interestingly, also memantine,
a drug that is already used to treat dementia in AD patients,
prevented memory loss induced by Aβ42 expression in flies[52]. Positive effects of the mentioned drugs were also
evident in double transgenic AD mice overexpressing
two mutated AD-linked transgenes (APPswe/PSEN1dE9)
[52,53]. Thus, results from invertebrate models systems
might be well transferred to higher organisms.
Accumulating evidence suggests that impairment of metal
homoeostasis is an important factor in AD pathogenesis.
Levels of redox active metal ions such as copper, zinc and
iron are elevated in amyloid plaques of AD patients
[54]. Furthermore, it is known that presence of metals can
promote Aβ aggregate formation in vitro and chelating
agents are able to dissolve Aβ plaques in post mortem AD
brains [55,56].
Drosophila models for AD proved to be a useful tool
to investigate the influence of different metal ions on
Aβ-induced neurodegeneration [57-61]. By feeding Aβ42
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Aβ42-induced phenotypes such as REP decreased survival
and locomotor defects were enhanced. In contrast, food
supplemented with metal-chelating substances suppressed
these phenotypes [57]. Genetic manipulation of metal
homeostasis further underlined the role of zinc and copper
levels in Aβ42-induced toxicity [57-59]. For example,
overexpression of MTF-1, a highly conserved transcription
factor inducing expression of several metal ion scavenger
proteins, was shown to effectively protect from detrimental
effects of Aß42 in flies [57]. Furthermore, genetic inhibition
of two copper-importers (Ctr1C and Ctr1B) ameliorated
Aß42-induced neurodegenerative phenotypes while lower-
ing copper load in the fly brain [58]. A study focusing on
zinc as another redox active metal and its modulation
of Aβ42-induced phenotypes basically showed the same
[59]. Genetic downregulation of the expression of the zinc
importer dZip1 consistently suppressed Aβ42-induced
brain vacuolization, locomotor defects and reduced life-
span, while overexpression had the opposite effect [59].
Furthermore, the authors were able to show an effect
of zinc deposition on the accumulation of Aβ fibrils in
Drosophila brains and a beneficial effect of dZip1
knockdown on Aβ-induced early memory loss [59].
While findings about the detrimental effects of metal
ion-Aβ complexes find a growing consent, not much is
known about the specific mechanisms of metal ions in AD.
The study of Liu et al. took a closer look on the biophysical
particularities of the interaction between iron and Aβ
peptides [60]. First, a connection between the presence
of iron and modulation of Aβ42-induced toxicity was
observed. Manipulation of the expression of iron-binding
proteins like ferritin and feeding of iron-specific chelating
agents altered Aβ42-induced toxicity [60]. Surprisingly,
knockdown of ferritin did not reduce Aβ accumulation
but efficiently suppressed Aβ42-induced toxicity [60].
Instead, biophysical techniques revealed that the presence
of iron during Aβ42 aggregation altered the structure of
Aβ fibrils delaying the formation of mature aggregates
[60]. Cytotoxicity assays using human neuroblastoma
SH-SY5Y cells indicated that the presence of iron during
aggregate formation was contributing to Aβ toxicity rather
than addition of iron after aggregate formation [60]. Thus,
the authors conclude that modulation of the kinetics of Aβ
aggregate formation by iron is important for the toxicity of
Aβ42 peptides [60].
Besides the potential function of metal ions to act as
seeds for Aβ accumulation, they might also play a role
in the production of reactive oxygen species (ROS) via
Fenton-like reactions. An unbiased screen identified many
modifiers of Aβ42-induced toxicity that were implicated
in redox regulation [61]. Overexpression of two subunits of
ferritin, a highly conserved protein with a strong antioxi-
dant potential, efficiently prolonged the lifespan of Aβ42expressing flies and simultaneously reduced the oxidative
damage in fly brains [61]. Thus, sequestration of free
radicals by ferroxidase activity might be a beneficial
mechanism protecting from oxidative stress originating
from the redox potential of Aβ peptides in the Drosophila
model for Aβ42-induced toxicity [61].
Further adding to the topic of metal ions interacting
with Aβ peptides is a study about intrinsic toxicity of
aluminum [62]. Typical neurodegenerative phenotypes
like reduced lifespan, locomotor deficits, olfactory learning
abnormalities and vacuolization of the brain were observed
after feeding Drosophila with excess aluminum [62].
Aluminum overload was shown to increase iron levels
while simultaneously generating ROS. However, no direct
link could be established between both processes [62].
Interestingly, expression of Aβ peptides or Tau did not
modulate the Al-induced neurotoxicity [62]. This study
indicates that heavy metal ions can exert neurotoxic
effects per se and it remains to be elucidated if these
mechanisms are the cause or consequence in the interplay
between redox reactive metal ions, ROS generation and
Aβ peptides.
Apart from Aβ42 deposits, AD in humans is character-
ized by intracellular neurofibrillary tangles composed
of hyperphosphorylated Tau proteins. As the functional
interactions between both AD lesions remain unclear, fly
lines expressing Aβ42 were investigated for the formation
of fibrillary structures with fly endogenous Tau protein.
However, fibrillary structures composed of hyperpho-
sphorylated Tau could not be detected in Aβ42-expressing
flies using biochemical or histological methods [51].
Drosophila models for Tau toxicity
Insoluble aggregates of the MT-associated protein Tau
are a common feature of so-called tauopathies like fronto-
temporal dementia with parkinsonism linked to chromo-
some 17 (FTDP-17), progressive supranuclear palsy
and Pick’s disease and others [63]. Central feature of
tauopathies is the presence of paired helical filaments,
which assemble into intracellular neurofibrillary tangles in
affected tissues [64]. Several disease-linked mutations in
the Tau gene affect correct splicing of its MT binding sites,
thus enhancing abnormal phosphorylation and detachment
of the protein. Both steps are believed to be crucial in
the process of forming paired helical filaments and higher
order neurofibrillary tangles [65,66].
Overexpression of wild-type or mutant human Tau in
the Drosophila nervous system caused vacuolization in the
brain accompanied by pathologic phosphorylation status of
Tau, although large filamentous aggregates were absent
[64]. Nevertheless, immunostaining with antibodies detect-
ing abnormal confirmation of Tau revealed a close associ-
ation between areas of degeneration and abnormal Tau in
flies. Moreover, the abundance of vacuolar lesions in the fly
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addition, neurodegeneration progressed with fly age and
eventually resulted in early mortality. Furthermore, severity
of phenotypes was enhanced by increasing Tau dosage
or introducing mutant Tau isoforms, such as the V337M
and R406W mutations associated with FTDP-17 [64]. In
addition, targeted expression of either wild-type or mutant
Tau in the retina caused alterations in external eye
structures, characterized by size reduction and rough
appearance. The so-called rough eye phenotype (REP)
correlates with the loss of retinal cells including photore-
ceptors [63,64,67,68]. Detailed analysis revealed that Tau
overexpression caused degeneration of photoreceptor axons,
evident by the appearance of vacuoles in the medulla,
the projection target of photoreceptor axons [63]. Such
REPs are frequently used to screen for genetic interactions
(see Table 2). In such an approach the fly ortholog of
glycogen synthase kinase 3β (GSK3β) was identified to
interfere with Tau-induced toxicity. Interestingly, the
Tau-induced REP was suppressed in a GSK3β-deficient
background and enhanced by GSK3β overexpression
[68]. Detailed analysis showed that overexpression of
GSK3β strongly increased pathogenic phosphorylation
of Tau [68,71].
In order to investigate the role of Tau phosphorylation
and toxicity in more detail, several Tau variants with
altered phosphorylation sites were generated [67,73,74].Table 2 Overview of performed large-scale screens for modifi
in Drosophila melanogaster
Transgene causing a REP Screened library
hTau[V337M] 2,276 EP strains
hTau[V337M] 1,250 P-element strains
hTau[WT] 920 P-lethal strains
895 EY strains
GMR > Aβ42 1,963 EP strains
Pan neural Arctic
Aβ42 life span reduction
3,000 de novo
insertions of transposable elements
The table lists only screens in which the fly was used as primary screening tool. No
in flies.Chatterjee et al. created fly lines expressing phosphoryl-
ation-resistant Tau variants by exchanging two (TauS2A) or
eleven (TauS11A) putative serine-threonine phosphorylation
sites with neutral alanine. These mutations prevented phos-
phorylation by protease activated receptor 1 (PAR-1) and
GSK3β, respectively [67]. This allowed a thorough investi-
gation of several Tau kinases in disease-related processes
such as site-specific phosphorylation and changes in
MT binding properties of Tau [67]. Interestingly, REP
enhancement induced by overexpression of GSK3β was
less pronounced in the TauS2A expressing fly compared to
the wild-type Tau expressing fly although immunoblotting
using phosphorylation site-specific Tau antibodies showed
a higher degree of Tau phosphorylation. In contrast,
TauS11A was resistant to GSK3β phosphorylation although
GSK3β overexpression enhanced the TauS2A-induced REP
severity. Furthermore, neither Tau aggregation nor MT
binding properties consistently correlated with REP [67].
These results uncouple Tau toxicity from sole phosphoryl-
ation and indicate Tau toxicity is partially independent of
its phosphorylation state.
In addition, Iijima-Ando et al. generated another
phosphorylation-resistant Tau variant TauS262A [73]. Retinal
coexpression of wild-type human Tau and DNA damage-
activated checkpoint kinase 2 (Chk2) resulted in enhance-
ment of the REP. In contrast, coexpression of Chk2 and
TauS262A had no effect on eye surface integrity [73].ers of toxicity induced by expression of AD-linked genes
Results Reference
• Kinases, phosphatases
(CDK5, GSK3β, PAR1)
Shulman & Feany [69]
• Apoptosis
• Novel: Ataxin 2, Fmr1
• Cytoskeletal components Blard et al. [70]
• Molecular chaperones
• Chromatin remodelling
• Kinases, Phosphatases Ambegaokar et al. [71]
• Autophagy/lysosomal
• RNA processing
• Chromatin regulation
• Cytoskeletal
• Secretory pathway Cao et al. [72]
• Cholesterol homeostasis
• Chromatin regulation
• Fenton chemistry and oxidative
stress are involved in AD pathology
Rival et al. [61]
• Ferritin expression
protects from β-amyloid toxicity
t listed are screens using other sources to gain candidates, later confirmed
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ation sites to Tau toxicity, Steinhilb et al. designed novel
Tau transgenes [74]. By replacing serines of several
disease-associated phosphorylation sites with alanine
they created a phosphorylation-resistant variant (TauAP)
and by replacing serines with glutamines they mimicked a
hyperphosphorylated state of Tau (TauE14). The conse-
quences are amelioration of Tau toxicity in flies expressing
phospho-deficient Tau variant TauAP and exacerbation of
Tau toxicity in flies expressing the phospho-mimetic Tau
variant TauE14 [74]. However, mutation of individual serines
of the respective phosphorylation sites did not result in a
clear modulation of Tau toxicity indicating that multiple
sites work in concert to confer to Tau toxicity [75].
Folwell and co-workers analyzed concomitant expression
of Aβ42 and Tau in flies. In these flies, Aβ42 expression
exacerbated Tau-induced neuronal dysfunction, axonal
transport deficits and decreased survival [76]. The com-
binatorial expression of both pathological proteins Aβ42
and Tau in Drosophila seems to be a promising approach
to investigate the synergistic effects at the level of genetic
interactions.
Large-scale screens in Drosophila
Low demand on care and easiness of handling predestine
the fly to high-throughput screens in vivo. Adding to these
advantages is the extraordinary large pool of available
genetic instruments paired with simplicity of the genomic
structure facilitating subsequent in-depth analysis.
Up to now unbiased screens in Drosophila were per-
formed utilizing the above-described tools and provided
valuable insights into AD pathomechanisms (see Table 2)
[69-72]. REPs induced by expression of toxic gene products
in the Drosophila compound eye represent an easy to score
read-out for genetic modifier screens. The fly eye is a
neuronal structure and REPs are highly sensitive to genetic
modification. Changes in REP severity usually coincide
with changes in photoreceptor degeneration, thus changes
in neuronal decline can be investigated by light microscopy
(Figure 2).
Shulman and Feany conducted the first large-scale
screen in Drosophila for genetic modifiers of toxicity
induced by expression of human Tau [69]. In their screen,
the authors used the fact that eye-specific expression
of a FTLD-linked Tau variant (Tau[V337M]) induced a
moderate REP. To facilitate identification of enhancers
and suppressors, flies with the Tau-dependent REP were
crossbred with a collection of 2,276 enhancer promoter
(EP) insertion-carrying flies. These files contain random
insertions of EP-elements, which can be used to misexpress
endogenous fly genes (Figure 1) [45]. EP-elements contain
UAS sites allowing the Gal4-induced transcription of open
reading frames in the vicinity of insertion. Depending on
the orientation of the EP-element in relation to the openreading frame, Gal4 induces either ectopic overexpression
or inactivation of the gene by RNA interference (RNAi)
[45]. After comprehensive validation of identified candi-
dates they were functionally classified. The largest group
of modifiers were kinases and phosphatases. Among these
kinases were Drosophila orthologs of known Tau kinases
such as cyclin-dependent kinase 5 (CDK5) and GSK3β.
Accordingly, these results confirmed the reliability of
the screening approach and emphasizes the critical role of
Tau phosphorylation for toxicity [69].
Using the same transgenic fly line expressing human
Tau [V337M], Blard et al. screened a different collection
of 1,250 EP-element containing fly lines [70]. According
to the differences in fly lines and the low percentage of
whole genome coverage, there was little overlap between
identified modifiers from this screen compared to the
screen by Shulman and Feany. Blard et al. identified
several components of the cytoskeleton as modifiers of
Tau-induced REP. In addition, the Tau-induced disruption
of the MT network at nerve terminals was identified as
key event leading to Tau-induced neurodegeneration [70].
The most recent large-scale screen for modifiers of Tau
toxicity was performed by Ambegaokar et al. [71]. In their
screen, the authors used a fly line expressing wild-type
human Tau in the fly eye. This fly line also exhibited an
intermediate REP, which was suitable to identify both
enhancer and suppressors. The authors screened two
independent collections of fly lines. The first contains
roughly 1,000 lethal loss-of-function alleles caused by
P-element insertion in essential genes. The second col-
lection contained 900 lines with random insertions of
EY-elements. These EY-elements are very similar to
EP-elements and also contain UAS sites. Once Gal4
is present, this can result in overexpression or RNAi-
mediated silencing of genes in close vicinity to the
insertion site of the element (Figure 1). In their screen,
Ambegaokar and co-workers identified known interac-
tors of Tau toxicity such as the Drosophila ortholog of
GSK3β. This can be regarded as validation of the screen
and suggests that identified modifiers could be relevant
to disease. Comprehensive analysis of identified modifiers
using computational network approach revealed a
broad range of functional classes including kinases,
cytoskeletal components as expected but also mechanisms
not yet associated to Tau toxicity such as RNA metabolism
or chromatin interaction [71]. Furthermore, the authors
found that differences in Tau phosphorylation did not
correlate with changes in Tau toxicity [71].
Only few large-scale screens have been published
identifying genetic modifiers of Aβ42-induced toxicity
(see Table 2 and [61,72]). Cao et al. screened a collection of
EP-element carrying fly lines for modification of Aβ42-
induced REP in Drosophila [72]. Modifiers identified in this
screen comprise loss-of-function alleles widely involved in
Figure 2 Exemplified rough eye phenotypes (REP) used as readout for modifier screens. Scanning electron micrographs (top) of fly eyes
are shown. The Drosophila compound eye consists of a stereotypic array of about 800 omatidia (left). These hexagonal structures are highly
ordered and display regular spacing of hairs called interomatidial bristles (inset). Expression of disease-linked proteins/peptides in the eye can
cause a REP (middle). The rough appearance of the eye can be caused by loss of interomatidial bristles, fusion of omatidia, necrotic tissue, dints
in the retina and is often accompanied by loss of pigmentation and reduced eye size. An enhancement in severity (left) is easily observable by
more pronounced REP characteristics. Usually, such REPs are sensitive towards genetic interactions, causing either a suppression (left) or an
enhancement (right), changing the overall eye appearance towards a more wild-type like appearance (suppression) or by increasing the rough
appearance of the eye (enhancement), respectively. Exemplary light micrographs show REPs induced by expression of either Tau[R406W] (middle)
or Aβ42 (bottom). These REPs are sensitive towards genetic modification like suppression (left) and enhancement (right) and can be/have been
used for screening approaches.
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clusion that proper function of endocytosis and vesicular
trafficking is critical to protect the cell from Aβ42-induced
toxicity. In addition, a reasonable number of candidate
genes involved in secretory pathways were identified.
Thus, the authors argue that proteolytic degradation of Aβ
peptides during translocation by the secretory pathways
might be a crucial pathomechanism in AD [72]. On the
other hand, Rival and co-workers convincingly showed that
Fenton chemistry and oxidative stress contribute to the
toxicity of β-amyloid peptides in flies [61].
The combination of the Aβ42-induced REP with the
utilization of RNAi allows for an unbiased screen targetingknown open reading frames of the Drosophila genome.
Using an inducible short hairpin RNA (shRNA) expressing
fly line, the RNAi effect can be activated in a spatio-
temporal manner (Figure 1). Recently, an in vivo RNAi
library was generated utilizing the UAS/Gal4 system to
control shRNA expression [47].
The RNAi library has been extensively used for genome-
wide, large-scale screens to identify genetic modifiers of
basic cellular mechanisms [77-79]. However, published
data regarding the above-described Aβ42 toxicity models are
surprisingly scarce [72,80]. Nevertheless, this approach has
been used to find genetic modifiers of Ataxin-3-derived
polyglutamine-induced toxicity [81]. The analysis yielded a
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of multiple processes in polyglutamine toxicity.
To aid the understanding of mechanisms leading to
AD, we performed a genome-wide screen for modifiers
of Aβ42-induced neurodegeneration [82]. By combining
eye-specific RNAi-mediated knockdown of single Dros-
ophila genes and concomitant Aβ42 expression, genetic
interactors modulating Aβ42-induced REP were identified
and were assigned to cellular pathways contributing to
Aβ42 toxicity. To prove adaptability of the performed
screen, we tested RNAi lines targeting corresponding
Drosophila orthologs of known susceptibility genes identi-
fied by genome-wide association studies (GWAS) for their
ability to modulate the Aβ42-induced REP. Preliminary
results indicate low conformity between the effects of
RNAi-mediated knockdown of susceptibility genes and
enhancement or suppression of Aβ42-induced REP (un-
published results). One way to explain this might be the
redundancy of affected pathways. Another possibility
might be low penetrance of the RNAi effect, although
the majority of the RNAi library was tested for effective
silencing of targeted genes [47]. Still, AD is not a mono-
genic disease and application of GWAS to identify human
risk factors failed to find new major genes relevant to all
AD patients [83]. In addition, we conducted a very similar
screen to identify modifiers of Tau[R406W]-induced
neurodegeneration. To our surprise, in this screen we only
identified a very small amount of modifiers (less than 100
out of roughly 8,000 screened RNAi lines modified the
Tau[R406W]-induced REP). Among the few candidates
were members of the dynein/dynactin complex. As silen-
cing members of the dynein/dynactin complex enhanced
the Tau[R406W]-induced toxicity, an impaired retrograde
axonal transport seems to contribute to Tau[R406W]-
induced toxicity (to be published elsewhere).
Perspectives and conclusion
Drosophila melanogaster is a useful in vivo tool to analyze
pathomechanisms in AD. For example, aggregation of
Aβ42 can be easily determined in flies. Thus, large collec-
tions of small compounds can be screened for their
potency to inhibit Aβ peptide aggregation [80]. Recently, a
compound (D737) was identified that effectively inhibited
fibril formation in vitro. Administration of this compound
to flies prevented early death usually observed after Aβ42
expression [80]. Such in vivo approaches might help in
drug development not only in case of AD, but also in the
context of other (neurodegenerative) diseases.
Furthermore, transgenic fly lines can be used to prove
efficiency of β-secretase steady-state inhibitors [84].
β-Secretase activity is the rate-limiting step during amyloi-
dogenic processing leading to the generation of pathogenic
Aβ peptides. Thus, β-secretase activity is a preferred target
for the development of pharmacological therapies againstAD. In vitro assays proved the activity of several engineered
β-secretase inhibitors but many failed in cellular assays
[85,86]. However, in vivo the endosomal localization of
β-secretase is essential for activity. Coupling of a sterol
moiety to the inhibitor resulted in successful delivery to
the endosomal membrane and efficient inhibition of
β-secretase cleavage of APP in several cell lines [84].
Furthermore, inhibition of β-secretase activity by the
sterol-coupled inhibitor was shown to be efficient in vivo
using the triple transgenic fly line expressing hAPP,
hBACE and dPsn created by Greeve et al. [36]. Transgenic
larvae fed with the membrane-tethered steady-state in-
hibitor showed increased hatching rates compared to
transgenic larvae fed with soluble inhibitor [84]. Thus,
flies expressing disease-related transgenes might be very
useful to prove hypotheses in vivo in a fast, effective and
economic manner.
Despite the efforts of countless scientists worldwide to
clarify the mechanisms underlying the most prevalent
form of dementia, it is still not possible to cure AD. Until
now therapies for AD have included only symptomatic
treatment and there is not even any effective medication
to stop disease progression. The mere number of hypoth-
eses intending to explain the pathogenesis of AD hints at
the general challenge this disease poses to modern
science. The challenge now is to elucidate the contribution
of AD-associated pathways with known effects to Aβ42-
induced neurodegeneration and to differentiate the path-
ways modifying general neurodegenerative mechanisms
from the ones that are unique to AD and thus provide
a target for drug development.Ethical approval
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